Racing to Cures: the U.S.-China Biomedical Competitiveness Scorecard

The United States has long assumed global leadership in biomedical innovation. How will it continue to retain its edge? China has dramatically accelerated its research output, clinical trial volume, and pharmaceutical pipeline, producing raw materials, creating drug discovery platforms, and commercializing world-class therapies while competing head- to-head in licensing and BD. Drawing on the Cure Innovation Index and a new survey of U.S. academics and industry leaders, moderator Seema Kumar will debut a U.S./China innovation scorecard to reveal the strengths, opportunities, and strategies driving stakeholders in each country's end-to-end innovation engine. Bringing together voices from industry, government, and academia, this session delivers data, debate, and actionable insights for institutions, investors, and industry to stay competitive.